The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Low-dose pembrolizumab in advanced NSCLC: implications for access and treatment pathways
Nandini Menon, MBBS, MD, DNB, Tata Memorial Centre, Mumbai, India, discusses the potential integration of low-dose pembrolizumab into treatment algorithms for advanced non-small cell lung cancer (NSCLC) alongside emerging first-line competitors. Dr Menon highlights the challenges of delivering immunotherapy in India due to high costs and lack of government insurance coverage, and notes that reducing the cost of pembrolizumab could make it more accessible to patients and increase its inclusion in standard treatment coverage. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
